



Contact:

Mia West
West Public Relations LLC
mwest@west-pr.com
619.501.2756

Frequentz Releases 2015 RxTrace U.S. Pharma Traceability Survey Findings

Serialization is a priority for most of the pharmaceutical supply chain, while a third fall behind partially due to unrealistic perception of upgrade effort needed

Palo Alto, CA – March 23, 2015 – According to the results from the 2015 RxTrace U.S. Pharma Traceability Survey, which was released today, the vast majority of companies are now working on meeting the 2015 Drug Supply Chain Security Act (DSCSA). However, a concerning third of companies have not begun working on adding serialization capabilities, with some having an unrealistic idea of the time needed to develop and deploy these upgrades. The second annual survey was conducted by RxTrace and sponsored by Frequentz Inc., a global leader and champion of end-to-end visibility.

“The survey represents an intimate look at the thinking and planning of supply chain companies as global compliance deadlines loom,” said Dirk Rodgers, founder of RXTrace.com. “We found that GS1’s EPCIS standard is the overwhelming choice for the internal repositories necessary for meeting the 2017 serialization mandate, and many respondents expect a shift to occur from the initial use of EDI ASNs to EPCIS events for the transaction data exchange before it will be necessary in 2023.”

To view the complete results from the survey, visit http://frequentz.com/news_media/download-survey-2015/.

About The Survey

In November of 2013, the federal DSCSA was enacted, creating new federal track and trace requirements for the pharmaceutical supply chain and preempting all state and federal serialization and pedigree laws. A total of 38 questions were asked to discover what the people who must meet the new DSCSA requirements are thinking. The survey was open to people who work for companies in the U.S. pharma supply chain and to solution providers targeting those businesses. Each respondent was asked questions that were pertinent to their type of business, so no individual was exposed to all 38 questions.

The Solution

People everywhere rely on the validity and safety of their medications to help



them live healthier lives. As the counterfeit drug market grows and supply chains become more complex, Frequentz provides businesses globally with cutting-edge pharmaceutical management technologies that help monitor products as they move through the supply chain and keep consumers safe. Benefits include:

- Flexible solutions addressing all the major chain of custody usage scenarios that pharmaceutical companies require for faster compliance and more operational efficiencies
- Nimble technology that can quickly adapt to current and emerging laws
- ERP and Middleware agnostic uniquely in a private cloud for data safety and independent validation procedures
- As a member of GS1 and leader in EPCIS standards since 2006, compliance managers coach clients through upcoming requirements and beyond
- A verification portal for downstream pharmaceutical trading partners that supports 67 percent of all pharmaceuticals distributed across the United States. This provides visibility into a drug's chain of custody and supports pharmaceutical's largest trading partner network.
- Mobile technologies that can help put safety right in a patient's hands by allowing them to authenticate a medicine, receive promotional announcements, adhere to refills and receive important, targeted messaging, and provide agencies FDA and DEA the ability to further target and eliminate illicit or counterfeit product within the global drug supply chain.

About Frequentz

Frequentz is a global leader and champion of end-to-end visibility, offering comprehensive traceability, serialization and information management technologies. Their transformative tools bolster businesses and brand reputations by improving productivity, product quality, and profitability. To accomplish this, Frequentz provides valuable insight into end-to-end supply chains, and critical business processes by collecting, storing and analyzing serialized, life history data. Applications of its software are currently used in the life sciences, agricultural, fishery and sustainability, retail, and automotive industries worldwide and promote intelligent analytics and consumer safety. For more information visit www.frequentz.com.

###